HistoSonics has raised $4.8 million in a new debt and warrants round of financing, according to a recently posted SEC filing.
HistoSonics is developing an image-guided, robotically assisted platform therapy using non-invasive and non-thermal technologies, according to the company’s website.
Money in the round came from 20 anonymous investors, with the first sale noted on April 18.
The Ann Arbor, Michigan-based company is looking for an additional $175,000 before closing the round, with a minimum investment of $50,000 required, according to the filing.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.